MacroGenics, Inc.
Bi-Specific Monovalent Diabodies That are Capable of Binding CD123 and CD3, and Uses Thereof

Last updated:

Abstract:

The present invention is directed to sequence-optimized CD123.times.CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.

Status:
Application
Type:

Utility

Filling date:

24 Aug 2020

Issue date:

18 Feb 2021